Loading...
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
Saved in:
| Published in: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469186/ https://ncbi.nlm.nih.gov/pubmed/30871014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12010037 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|